Cabotegravir + Levonorgestrel Long-Acting MPT Injectable
CAB + LNG Injectable
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): CONRAD
Details
- API: Cabotegravir, Levonorgestrel
- Target: Progesterone Receptors
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Inhibition of Sperm Motility
- Ovulation Inhibition
- Anti-Microbial
- Inactive Materials: Silica, Water
- Regimen: 1 Injection/6 Months
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention. This injectable is discreet and only requires a clinical visit 2 times a year.
Product Status
Recent Pre-Clinical Research. Research was funded by USAID through the MATRIX drug development program, which was terminated in 2025. Record will be monitored for potential status change to inactive.
History
During a MATRIX investigator meeting in 2023, it was reported that work is ongoing to optimize the CAB/LNG hydrogel formulation for extended (6 months) duration.